EXEL
EXEL clinical trials: EXELIXIS, INC.
Every trial on ClinicalTrials.gov where EXELIXIS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 157
- Trials linked
- 57
- As lead sponsor
- 100
- As collaborator
- 3
- Primary completions as lead sponsor, next 90 days
EXEL on the catalyst calendar · EXEL registry changes
- Primary completion Nov 30, 2027Sponsor estimatePhase 1NCT07123103A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid TumorsExelixis · Solid TumorsRecruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 5, 2030Sponsor estimatePhase 3NCT07750158Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With...Exelixis · Colorectal CancerRecruitingEXELLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 15, 2028Sponsor estimatePhase 2NCT07845786Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)Exelixis · Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2027Sponsor estimatePhase 1NCT05932862A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsExelixis · Advanced Solid TumorActive, not recruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2029Sponsor estimatePhase 2/Phase 3NCT06943755Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsExelixis · Pancreatic Neuroendocrine Tumor (pNET)RecruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2026Sponsor estimatePhase 1NCT06545331Study of XB010 in Subjects With Solid TumorsExelixis · Locally Advanced or Metastatic Solid TumorsRecruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2030Sponsor estimatePhase 3NCT07620574Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyExelixis · CancerEnrolling by invitationEXELLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 29, 2028Sponsor estimatePhase 2NCT07428616A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaExelixis · MeningiomaRecruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 1NCT05176483Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsExelixis · Renal Cell Carcinoma (RCC)RecruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2022ActualPhase 3NCT03937219Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal...Exelixis · Renal Cell CarcinomaActive, not recruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 19, 2020ActualPhase 3NCT03690388A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed...Exelixis · Differentiated Thyroid CancerActive, not recruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 21, 2023ActualPhase 1NCT03170960Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsExelixis · Urothelial CarcinomaActive, not recruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 15, 2020ActualPhase 4NCT01896479A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid CancerExelixis · Medullary Thyroid CancerActive, not recruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2028Sponsor estimatePhase 1NCT07773454Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid TumorsExelixis · CancerNot yet recruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 3NCT05678673Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaExelixis · Non-Clear Cell Renal Cell CarcinomaActive, not recruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 16, 2026ActualPhase 3NCT05425940Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerExelixis · Colorectal CancerActive, not recruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2027Sponsor estimatePhase 1NCT06952010A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid TumorsExelixis · Solid TumorRecruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2011ActualPhase 2NCT01068782Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second RelapseExelixis · Astrocytic TumorsTerminatedEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2014ActualPhase 2NCT01995058Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCExelixis · Prostate CancerTerminatedEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2, 2012ActualPhase 1/Phase 2NCT00596648A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)Exelixis · Carcinoma, Non-Small-Cell LungCompletedEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 19, 2024ActualPhase 3NCT04446117Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCExelixis · Metastatic Prostate CancerActive, not recruitingEXELLeadTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2021ActualPhase 3NCT03755791Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who...Exelixis · Hepatocellular CarcinomaActive, not recruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2028Sponsor estimatePhase 2/Phase 3NCT06082167Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck...Exelixis · Head and Neck Squamous Cell CarcinomaActive, not recruitingEXELLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 7, 2025ActualPhase 1NCT06630247A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid TumorsExelixis · Solid CancersTerminatedEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2025Sponsor estimatePhase 1NCT06962332Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)Exelixis · Hepatic ImpairmentRecruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 132 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner